Suppr超能文献

羟基脲治疗不可切除的生长缓慢的脑膜瘤。

Non-resectable slow-growing meningiomas treated by hydroxyurea.

作者信息

Loven David, Hardoff Ruth, Sever Zvi Bar, Steinmetz Adam P, Gornish Michael, Rappaport Zvi H, Fenig Eyal, Ram Zvi, Sulkes Aaron

机构信息

Institute of Oncology, Ha'Emek Medical Center, Afula, Israel.

出版信息

J Neurooncol. 2004 Mar-Apr;67(1-2):221-6. doi: 10.1023/b:neon.0000021827.85754.8e.

Abstract

PURPOSE

To test the benefit of hydroxyurea in the treatment of recurrent and non-resectable slow-growing meningiomas.

METHODS

Twelve patients with regrowing non-malignant meningiomas, were enrolled for a protocol of 2 years with continuous chemotherapy with hydroxyurea, 20 mg/kg/day. Response to treatment was evaluated both clinically and by diagnostic imaging using computed tomography (CT) and 201-Thallium single photon emission CT. One minimal response was documented by CT, accompanied by clinical stabilization. Nine patients showed progressive disease, at least by one imaging procedure, with a median time to progression of 13 months (range 4-24). Two other patients were not available for response due to early removal from the study, following abrupt manifestation of grades 3-4 hematological toxicity.

CONCLUSION

In this series hydroxyurea has not shown effectiveness in the treatment of non-resectable slow-growing meningiomas: neither for achieving response, nor for arresting disease progression.

摘要

目的

测试羟基脲在治疗复发性和不可切除的生长缓慢的脑膜瘤中的疗效。

方法

12例非恶性脑膜瘤复发患者参加了一项为期2年的方案,持续使用羟基脲化疗,剂量为20mg/kg/天。通过临床评估以及使用计算机断层扫描(CT)和铊-201单光子发射CT进行诊断成像来评估治疗反应。CT记录到1例最小反应,伴有临床病情稳定。9例患者至少通过一种成像检查显示疾病进展,进展的中位时间为13个月(范围4-24个月)。另外2例患者因在出现3-4级血液学毒性后被提前退出研究而无法评估反应。

结论

在本系列研究中,羟基脲在治疗不可切除的生长缓慢的脑膜瘤方面未显示出有效性:既未实现反应,也未阻止疾病进展。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验